NCT03675139View on ClinicalTrials.gov

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

PHASE3CompletedINTERVENTIONAL
Enrollment

471

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

May 14, 2022

Study Completion Date

May 15, 2022

Conditions
Endometrial Hyperplasia Without Atypia
Interventions
DRUG

Medroxyprogesterone Acetate

At a dosage of 10mg/day

DRUG

Dydrogesterone 10 MG

At a dosage of 20 mg/day

Trial Locations (1)

200011

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Xiaojun Chen

OTHER

NCT03675139 - MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia | Biotech Hunter | Biotech Hunter